Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis Tomohiro FunakoshiMaya SuzukiHyman B. Muss Review 11 November 2014 Pages: 321 - 330
Taking the next step: a systematic review and meta-analysis of physical activity and behavior change interventions in recent post-treatment breast cancer survivors Shirley M. BluethmannSally W. VernonL. Kay Bartholomew Review 03 January 2015 Pages: 331 - 342
The prognostic relevance of the mitotic activity index in axillary lymph node-negative breast cancer Jan J. JobsenJob van der PalenHenk Struikmans Preclinical study 21 December 2014 Pages: 343 - 351
Biological and clinical significance of PARP1 protein expression in breast cancer Andrew R. GreenDaniela CaracappaEmad A. Rakha Preclinical Study Open access 21 December 2014 Pages: 353 - 362
INPP4B and RAD50 have an interactive effect on survival after breast cancer Xiaofeng DaiRainer FagerholmHeli Nevanlinna Preclinical study 21 December 2014 Pages: 363 - 371
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib N. ElsterM. CremonaA. J. Eustace Preclinical study 21 December 2014 Pages: 373 - 383
Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients C. Benitez-BuelgaL. Sanchez-BarrosoJ. Benitez Preclinical Study 21 December 2014 Pages: 385 - 394
C-kit overexpression correlates with KIT gene copy numbers increases in phyllodes tumors of the breast Junjun LiuXiaozhen LiuYun Niu Preclinical Study 23 December 2014 Pages: 395 - 401
Divergent roles of CXCR3 isoforms in promoting cancer stem-like cell survival and metastasis Yanchun LiJocelyn C. ReaderAmy M. Fulton Preclinical study 24 December 2014 Pages: 403 - 415
Long-term clinical outcomes in women with breast pain in the absence of additional clinical findings: mammography remains indicated Mitra NoroozianLauren F. SteinMark A. Helvie Preclinical study 06 January 2015 Pages: 417 - 424
Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy Adam D. PfefferleBenjamin T. SpikeCharles M. Perou Preclinical Study Open access 10 January 2015 Pages: 425 - 437
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial Shuzhen LiuJudy-Anne W. ChapmanKaren A. Gelmon Clinical Trial 01 January 2015 Pages: 439 - 448
Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial Claudia M. WittOskar AußererLena Schützler Clinical trial 03 January 2015 Pages: 449 - 460
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01) S. de GrootL. G. M. JanssenJ. R. Kroep Clinical trial Open access 04 January 2015 Pages: 461 - 466
Increased pSmad2 expression and cytoplasmic predominant presence of TGF-βRII in breast cancer tissue are associated with poor prognosis: results from the Shanghai Breast Cancer Study Qingchao QiuYinghao SuQiuyin Cai Epidemiology 27 December 2014 Pages: 467 - 477
Premenopausal plasma 25-hydroxyvitamin D, mammographic density, and risk of breast cancer Kimberly A. BertrandBernard RosnerRulla M. Tamimi Epidemiology 28 December 2014 Pages: 479 - 487
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer Anthony F. YuNandini U. YadavRichard M. Steingart Epidemiology 01 January 2015 Pages: 489 - 495
Autoimmune diseases and breast cancer recurrence: a Danish nationwide cohort study Lone Winther LietzenDeirdre Cronin-FentonTimothy L. Lash Epidemiology 03 January 2015 Pages: 497 - 504
History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response Louise HuzellMia PerssonHelena Jernström Epidemiology 04 January 2015 Pages: 505 - 515
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2 Celine M. VachonDaniel J. SchaidFergus J. Couch Epidemiology 10 January 2015 Pages: 517 - 523
Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis María de PedroSara BaezaJavier Llorca Epidemiology 15 January 2015 Pages: 525 - 536
The impact of cancer prevention guideline adherence on overall mortality in a high-risk cohort of women from the New York site of the Breast Cancer Family Registry Ann J. CloudAshley ThaiMary Beth Terry Epidemiology Open access 21 January 2015 Pages: 537 - 546
Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry Tú Nguyen-DumontFleur HammetMelissa C. Southey Brief Report 10 January 2015 Pages: 547 - 554
Invasive lobular carcinoma of the breast: local recurrence after breast-conserving therapy by subtype approximation and surgical margin Lior Z. BraunsteinJane E. BrockJay R. Harris Brief Report 21 January 2015 Pages: 555 - 564
Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure Suleiman MassarwehEdward RomondRichard Elledge Erratum 21 January 2015 Pages: 565 - 565
Erratum to: Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis C. A. DrukkerS. G. EliasE. J. Th. Rutgers Erratum 21 January 2015 Pages: 567 - 567
